Including commercially available innovative products and technologies
Yissum - Research Development Company of the Hebrew University posted this:Innovative Skin Non-penetrating Products Containing Sunscreen MoleculesKeywords: cosmetics, sunscreens Project ID : 6-2006-191
Yissum - Research Development Company of the Hebrew University posted this:CBD treatment for Hepatic Encephalopathy, Liver Cirrhosis and NASHA method for the treatment of hepatic encephalopathy comprising administering to a subject in need of such treatment an effective amount of D9-tetrahydrocannabinol (THC) or Cannabidiol. keywords: hepatic, encephalopathy Originally: 12-2007-1885, 12-2007-1878 12-2006-577- 3 projects combined into one Project ID : 12-2006-577
Yissum - Research Development Company of the Hebrew University posted this:Novel Compounds for the treatment of obesityNovel Compounds for the treatment of obesity Project ID : 6-2008-1996
Yissum - Research Development Company of the Hebrew University posted this:New passion-fruit cultivar bears fruit that remain on the vineCluster11 Dena 428 ‘Ripens during summer’ - a new variety of the Passion Dream cultivar - bares sweet, exotic flavored fruit that remains on the vine when ripened, providing a continuous flow of produce throughout most of the year. Project ID : 8-2010-2368
Yissum - Research Development Company of the Hebrew University posted this:Novel Compounds for the Treatment and Prevention of Autismbeta- carotene as treatment for autism Project ID : 6-2014-3058
Yissum - Research Development Company of the Hebrew University posted this:New Formulations for Oral, Nasal, Transdermal and Rectal CannabinoidsCluster9 CBD Project ID : 6-2017-4448
Yissum - Research Development Company of the Hebrew University posted this:Treating Skin Toxicities Caused by Biological Cancer Drugs Applying Topical Specific Inhibitors to the Anti-Cancer DrugsCluster8 Many of the antineoplastic tyrosine kinase inhibitors are associated with prominent and sometimes dose-limiting dermatologic complications. Of severe clinical implication are the specific EGFR inhibitors. Most patients treated with these drugs suffer from severe impairment to their quality of life and require reduction or interruption in the anti-cancer drug protocols. Treatment strategies today for treating skin toxicities from EGFR inhibitors show limited benefit and most patients require dose reductions or interruptions to the anti-cancer treatment protocols. Our proposal focuses on the development of a novel approach using formulation for treating skin toxicities caused by anti-neoplastic EGFR inhibitors by applying topical compounds that specifically and locally block the anti-cancer drugs. Our preliminary results have shown that blocking EGFR inhibitors binding to EGFR prevents keratinocyte death. We have identified small compounds that block EGFR inhibitors binding to its receptor and have developed topical slow release system that can deliver the target compounds to the hair follicle which is a major target for skin rash caused by EGFR inhibitors. Our novel approach will improve the quality of life of patients suffering from skin toxicity and help maintain an optimal anti-neoplastic dose thereby allowing more patients to receive full dose anti-cancer therapy and improve response to therapy Project ID : 6-2017-4450
Yissum - Research Development Company of the Hebrew University posted this:High Performance Fault Tolerant Matrix Multiplication AlgorithmsHigh Performance Fault Tolerant Matrix Multiplication Algorithms Project ID : 10-2017-4458
Yissum - Research Development Company of the Hebrew University posted this:Novel Autotaxin Inhibitor Drug (XIIPHONATE) for Cancer and/or AsthmaCluster8 We propose a novel compound for the treatment of asthma. We suggest to use this new compound named XIIPHONATE as new lipid-mimetic molecule that inhibits recombinant Autotaxin (ATX), as a potential local, long-term treatment for asthma. This approach is based on the fact that a novel bioactive lipid mediator, Lysophosphatidic acid (LPA), has a pivotal role in the pathogenesis of asthma. It was reported that LPA is synthesized from LPC through the enzymatic activity of ATX. Clinical data show that the levels of ATX protein, and LPA are significantly elevated the in airspaces of patients with asthma. Thus, XIIPHONATE, will inhibit LPA overproduction that leads to the pathologic state. It will therefore present a new therapeutic modality for asthma. Project ID : 6-2016-4268
Yissum - Research Development Company of the Hebrew University posted this:Eye-tracking technology detects when a face looks familiarEye-tracking technology detects when a face looks familiar Project ID : 37-2017-4394
Jim Pantzos posted this:
Founder at Resetfoods
Institute of Chemical Research of Catalonia posted this:Laboratory-scale photoreactors for high-througput experimentationWe are seeking licensees for the manufacture and commercialization of market-ready photoreactors with full control on temperature and light intensity. The developed photoreactors comprise several reaction spaces in order to allow parallel experimentation and reaction optimization.
Universitat de Girona posted this:Design and 3D reconstruction of the human skull applying the geometric abstraction method (Y-CR@NIUM)The Y-Cr@nium technology consists of a 3D geometrical model that systematizes the 22 cranial bones. It demonstrates what is the mechanical behavior of the skull in case of impact and therefore changes the paradigm when designing cranial prostheses and protective equipments such as motorcycle helmets or dummies.
Universitat de Girona posted this:Web-CDSS HTE 3.0 familiar hypercolesterolimiaThe present technology is a Web application integrable in a public or private health system, which facilitates the detection of dyslipidemia in general, and familiar hypercholesterolemia in particular. WEB-CDSS HTE 3.0 allows to customize the hypolipidemic treatment, considering its cardiovascular risk, concomitant diseases and drugs.It is based on the European Dyslipemia Guidelines of 2016